News and Events

Press Releases

June 21, 2022

Groundbreaking Data-Sharing Initiative Launches to Increase Understanding of Antimicrobial Resistance

Venatorx is excited to be a part of this significant collaborative initiative that will enhance and centralize access to high-quality AMR surveillance data across multiple datasets around the globe. Vivli’s AMR Register is vital to support educational and scientific communications on the AMR burden and emerging resistance, as well as global public health at large.

April 04, 2022

Venatorx Pharmaceuticals Raises Series C Financing Led by the AMR Action Fund

Venatorx Pharmaceuticals announced that it sold shares of its Series C Preferred Stock in a financing led by the AMR Action Fund with participation from existing investors including Abingworth.

March 10, 2022

Venatorx Pharmaceuticals Announces Positive Results for Phase 3 Clinical Trial (CERTAIN-1) of Cefepime-Taniborbactam for Treatment of cUTI

Venatorx Pharmaceuticals today announced positive results from its pivotal Phase 3 study evaluating cefepime-taniborbactam, an investigational new drug, as a potential treatment for adult patients with complicated urinary tract infections (cUTI), including acute pyelonephritis.

More Press Releases

In the News

May 24, 2022

The Hill

Antibiotic Resistance: A Looming Public Health Crisis

What threats do antibiotic-resistant superbugs pose for the future? What is being done to develop new antibiotics and bring life-saving drugs to market? And how can policymakers stimulate innovative drug developments to keep pace with evolving diseases?

April 04, 2022

STAT News

Pharma’s ambitious new antibiotic venture fund makes its first investments

One year after its splashy launch, the AMR Action Fund has made its first investments in a pair of fledgling biotech companies, a key step toward its goal of generating badly needed medicines to combat antibiotic resistance.

April 04, 2022

PharmaPhorum

Pharma-backed antibiotic fund makes first investments

AMR Action Fund said this morning that the first two beneficiaries are Adaptive Phage Therapeutics (APT) and Venatorx Pharmaceuticals, two biotechs that according to AMR Action Fund chief executive Henry Skinner “are poised to change the treatment landscape for drug-resistant infections.”

more news

Social Media

Retweet on Twitter Venatorx Pharmaceuticals Retweeted

; G20 Health & Development Partnership @G20Partnership ·

2 Sep 1565706612869894149

Henry Skinner, CEO of @AMRActionFund says we need data to identify the prevalence of AMR and we need partners with expertise to respond to where the needs are greatest

#H20Summit

Reply on Twitter 1565706612869894149 Retweet on Twitter 1565706612869894149 8 Like on Twitter 1565706612869894149 23 Twitter 1565706612869894149

Retweet on Twitter Venatorx Pharmaceuticals Retweeted

; World Anti-Microbial Resistance Congress @AMRCongress ·

23 Aug 1562165815478292482

2 weeks until World Anti-Microbial Resistance Congress - join us this September 7- September 8 at the Gaylord National Resort & Convention Center in National Harbor, MD

Register today: https://rb.gy/ljkhhw

Reply on Twitter 1562165815478292482 Retweet on Twitter 1562165815478292482 10 Like on Twitter 1562165815478292482 16 Twitter 1562165815478292482

Upcoming Events

IDWeek 2022

Wednesday, October 19, 2022 - Sunday, October 23, 2022

ECCMID 2023

Wednesday, April 05, 2023 - Saturday, April 15, 2023

More events